samedan logo
home > news > detailed info

RoslinCT to Participate in the Northern Alliance Advanced Therapies Treatment Centre

RoslinCT, a UK-based cell and gene therapy contract manufacturing organisation, is delighted to be part of the Northern Alliance Advanced Therapies Treatment Centre (NAATTC) consortium. As an industry partner within the consortium, RoslinCT will provide advice on the development, manufacture and clinical supply of cell, gene and tissue engineered therapies.

Unlike most conventional medicinal products, advanced therapies offer the potential to cure many degenerative diseases where cells and tissues can be regenerated, replaced or repaired, rather than as a standard treatment for the symptoms of the disease. These novel advanced therapies require modified supply strategies to ensure successful delivery to the NHS, thereby enabling increased access by patients throughout the UK.

The NAATTC successful 7 million Innovate UK bid was won by a consortium from Scotland and the North of England, bringing together expertise from advanced therapies companies, GMP manufacturing organisations, NHS organisations and Universities in the region. Twenty partners will work collectively towards addressing the practical issues relating to the manufacture and supply, evaluation, funding and adoption of this new generation of cell, gene and tissue engineered therapies.

The NAATTC will also collaborate with the other two Innovate UK funded Advanced Therapies Treatment Centres based around Manchester and the Midlands and Wales. The Treatment Centres, co-ordinated by the Cell and Gene Therapy Catapult, aim to cement the UKs position as a leader in the field of regenerative medicine.

Janet Downie, CEO of RoslinCT, said:

We are delighted to be involved in the NAATTC and bring our experience in the development and GMP manufacture of cell therapies for use in clinical trials to the consortium. We understand the practical issues in establishing integrated supply chain systems to ensure safe and efficient delivery of these novel therapies to patients and are looking forward to working with the consortium partners to develop best practice guidelines for the implementation of such procedures within the UK. We are grateful that Innovate UK is continuing to invest in these potentially life changing therapies and in the sector as a whole.

For more information, please contact:

Fiona Bellot, Business Development Manager
Tel: +44 (0)131 658 5180
Mobile: +44 (0)7867494071

About RoslinCT

RoslinCT is a Contract Development and Manufacturing Organisation (CDMO) based in the UK. RoslinCT offers a range of integrated services from technology transfer, process and assay development through to GMP manufacturing, storage, QP certification and batch release of cell-based therapies for clinical trials.
RoslinCT has a vision to lead the field in cell and gene therapy manufacturing and be the global partner of choice, building success on expert knowledge, progressive partnerships and with drive to deliver life-changing cell-based products to patients in need. This together with a passion for innovation and a flexible and personalised approach enables RoslinCT to engage with leading cell and gene therapy developers and to provide support at every step of the cell therapy development journey.

For more information please visit

About The Northern Alliance Advanced Therapies Treatment Centre (NAATTC)

The Northern Alliance is a partnership between advanced therapies companies, universities and the NHS, covering the North of England and the whole of Scotland.

The Northern Alliance Advanced Therapies Treatment Centre partners are:

Autolus, Chiesi Ltd, Cell Medica, Asymptote (part of GE Healthcare), RoslinCT, Datatrial, TrakCel, Alcyomics, World Courier, Fisher BioServices (part of Thermo Fisher Scientific), Miltenyi Biotec, Newcastle upon Tyne Hospitals NHS Foundation Trust, the Scottish National Blood Transfusion Service, the Leeds Teaching Hospitals NHS Trust, NHS Lothian, NHS Greater Glasgow and Clyde, NHS Blood and Transplant, The Academic Health Science Network for the North East and North Cumbria, Newcastle University and the University of Edinburgh.

About the Cell and Gene Therapy Catapult

The Cell and Gene Therapy Catapult was established as an independent centre of excellence to advance the growth of the UK cell and gene therapy industry, by bridging the gap between scientific research and full-scale commercialisation. With more than 120 employees focusing on cell and gene therapy technologies, it works with partners in academia and industry to ensure these life-changing therapies can be developed for use in health services throughout the world. It offers leading-edge capability, technology and innovation to enable companies to take products into clinical trials and provide clinical, process development, manufacturing, regulatory, health economics and market access expertise. Its aim is to make the UK the most compelling and logical choice for UK and international partners to develop and commercialise these advanced therapies.

About Innovate UK

Innovate UK is the UK's innovation agency. Innovate UK drives productivity and growth by supporting businesses to realise the potential of new technologies, develop ideas and make them a success. Innovate UK funds, supports and connects innovative businesses through a unique mix of people and programmes to accelerate sustainable economic growth.

Print this page
Send to a friend
News and Press Releases

Clinical and Regulatory Operational Excellence Forum

1. Innovative technologies are expected to take clinical development, licensing, and other regulatory processes to the next level in the future. What do you see are the biggest challenges facing companies when trying to cope with continued data growth in a fast changing environment? Pharmaceutical companies are heavily regulated and introducing change needs proof of acceptance by the authorities. The chance that authorities do not agree with that change makes the industry risk averse. Changes in a stable GxP environment are almost by default seen as a risk, however, not adapting to new technologies should also be seen as a risk! Therefore, ICH developed the ICH Q8, Q9, Q10, Q11, and Q12 guidelines, to anticipate change and implement changes much faster, with less of a regulatory burden. Nevertheless, industry is not picking up with the desired pace. Why not?
More info >>

White Papers

New Temperature Profiles from a Global Study

Laminar Medica

Recently there has been an influx of temperature mapping studies to collect sufficient ambient data to develop temperature profiles.  Solid temperature profiles on specific shipping routes are required to ensure streamlined packaging and robust lane qualification. The most reliable method to develop temperature profiles is to capture the actual reading from shipments, as well as using the historical and meteorological data to increase the confidence level.
More info >>

Industry Events

Pre-Filled Syringes & Injectable Drug Devices Europe

16-17 January 2019, Copthorne Tara Hotel, London

SMi is proud to present their 11th annual European conference and exhibition, within the Pre-Filled Syringes series: Pre-Filled Syringes & Injectable Drug Devices Europe. The event will take place on the 16th-17th of January 2019, in London.
More info >>

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement